Highlights Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
21.13 ^USD	-2.54%		+1.54%	-41.85%

May. 28	Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	MT
May. 28	Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	May. 28	MT
Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	May. 28	CI
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $50,000	May. 08	MT
Prothena Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Prothena Posts Q4 Net Loss as Revenue Slumps	Feb. 15	MT
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q4 Revenue $316,000, vs. Street Est of $2.72M	Feb. 15	MT
Prothena Corporation plc Provides Earnings Guidance for the Year 2024	Feb. 15	CI
Prothena Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q3 Revenue $84.9M, vs. Street Est of $41.7M	Nov. 02	MT
Prothena Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Prothena Reportedly Prepares for Potential Sale	23-10-16	CI
Prothena preparing for a potential sale - Bloomberg News	23-10-16	RE
Prothena Exploring Sale of Company; Shares Rise	23-10-16	MT
Prothena Rises Past 14% After Report Company Mulling Potential Sale Among Other Strategic Options	23-10-16	MT
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q2 Revenue $4M, vs. Street Est of $4.52M	23-08-03	MT
Prothena Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International ConferenceÂ®? 2023	23-07-17	CI
Prothena Corporation plc Announces Bristol Myers Squibb Opt-In for Worldwide Rights of Prx005, A Novel Anti-Mtbr-Tau Antibody	23-07-10	CI
Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab	23-06-27	CI
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $2.2M, vs. Street Est of $7.53M	23-05-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Highlights

Filters